BACKGROUND: We retrospectively explored changes in immunological parameters in men with biochemically recurrent prostate cancer treated with either 5 or 25 mg oflenalidomide in a randomized phase 2 trial, and determined whether those changes correlated with disease progression. METHODS:Cytokine levels were compared for each patient at baseline and after 6 months of treatment with lenalidomide. Regression models for correlated data were used to assess associations of cytokine levels with lenalidomide treatment effect. Estimates were obtained using generalized estimating equations. Changes in circulating anti-prostate antibodies were evaluated using a high-throughput immunoblot technique. RESULTS: Treatment with lenalidomide was associated with global changes in immunoreactivity to a number of prostate-associated antigens, as well as with changes in circulating levels of the T(H) 2 cytokines IL-4, IL-5, IL-10, and IL-13. Disease progression in treated patients was associated with an increase in circulating IL-8 levels, while IL-8 levels decreased significantly in non-progressors. CONCLUSIONS:Lenalidomide demonstrates immunomodulatory properties in patients with biochemically recurrent prostate cancer. The induction of novel anti-prostate antibodies is a potential mechanism for lenalidomide response. Changes in serum IL-8 levels may serve as a potential biomarker in treated patients. These hypotheses require formal testing in future prospective trials.
RCT Entities:
BACKGROUND: We retrospectively explored changes in immunological parameters in men with biochemically recurrent prostate cancer treated with either 5 or 25 mg of lenalidomide in a randomized phase 2 trial, and determined whether those changes correlated with disease progression. METHODS: Cytokine levels were compared for each patient at baseline and after 6 months of treatment with lenalidomide. Regression models for correlated data were used to assess associations of cytokine levels with lenalidomide treatment effect. Estimates were obtained using generalized estimating equations. Changes in circulating anti-prostate antibodies were evaluated using a high-throughput immunoblot technique. RESULTS: Treatment with lenalidomide was associated with global changes in immunoreactivity to a number of prostate-associated antigens, as well as with changes in circulating levels of the T(H) 2 cytokines IL-4, IL-5, IL-10, and IL-13. Disease progression in treated patients was associated with an increase in circulating IL-8 levels, while IL-8 levels decreased significantly in non-progressors. CONCLUSIONS:Lenalidomide demonstrates immunomodulatory properties in patients with biochemically recurrent prostate cancer. The induction of novel anti-prostate antibodies is a potential mechanism for lenalidomide response. Changes in serum IL-8 levels may serve as a potential biomarker in treated patients. These hypotheses require formal testing in future prospective trials.
Authors: Ling Lu; Faribourz Payvandi; Lei Wu; Ling-Hua Zhang; Robert J Hariri; Hon-Wah Man; Roger S Chen; George W Muller; Christopher C W Hughes; David I Stirling; Peter H Schafer; J Blake Bartlett Journal: Microvasc Res Date: 2008-09-04 Impact factor: 3.514
Authors: Xiaoju Wang; Jianjun Yu; Arun Sreekumar; Sooryanarayana Varambally; Ronglai Shen; Donald Giacherio; Rohit Mehra; James E Montie; Kenneth J Pienta; Martin G Sanda; Philip W Kantoff; Mark A Rubin; John T Wei; Debashis Ghosh; Arul M Chinnaiyan Journal: N Engl J Med Date: 2005-09-22 Impact factor: 91.245
Authors: Faribourz Payvandi; Lei Wu; Syedah D Naziruddin; Maura Haley; Anastasia Parton; Peter H Schafer; Roger S Chen; George W Muller; Christopher C W Hughes; David I Stirling Journal: J Interferon Cytokine Res Date: 2005-10 Impact factor: 2.607
Authors: Edward J Dunphy; Jens C Eickhoff; Charles H Muller; Richard E Berger; Douglas G McNeel Journal: J Clin Immunol Date: 2004-09 Impact factor: 8.317
Authors: Lei Wu; Mary Adams; Troy Carter; Roger Chen; George Muller; David Stirling; Peter Schafer; J Blake Bartlett Journal: Clin Cancer Res Date: 2008-07-15 Impact factor: 12.531
Authors: J B Bartlett; A Michael; I A Clarke; K Dredge; S Nicholson; H Kristeleit; A Polychronis; H Pandha; G W Muller; D I Stirling; J Zeldis; A G Dalgleish Journal: Br J Cancer Date: 2004-03-08 Impact factor: 7.640
Authors: Douglas G McNeel; Heath A Smith; Jens C Eickhoff; Joshua M Lang; Mary Jane Staab; George Wilding; Glenn Liu Journal: Cancer Immunol Immunother Date: 2011-12-31 Impact factor: 6.968
Authors: Jessica E Hawley; Samuel Pan; William D Figg; Zoila A Lopez-Bujanda; Jonathan D Strope; David H Aggen; Matthew C Dallos; Emerson A Lim; Mark N Stein; Jianhua Hu; Charles G Drake Journal: Prostate Date: 2020-01-03 Impact factor: 4.104
Authors: Krizia Rohena-Rivera; María M Sánchez-Vázquez; Diana A Aponte-Colón; Ingrid S Forestier-Román; Mario E Quintero-Aguiló; Magaly Martínez-Ferrer Journal: PLoS One Date: 2017-04-05 Impact factor: 3.240